MetaCap

GH Research PLC (GHRS)

NASDAQ: GHRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

17.53-1.03 (-5.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GHRS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.94
52-week range
12.04 – 31.44
Day range
17.29 – 18.32
Volume / Avg
298.83K / 294.69K
Beta
—

52-week range

$12.04$31.44

GHRS stock today

GH Research (GHRS) closed at $17.53 on Nov 20, down 5.55% (-$1.03), versus the S&P 500's 3.70% decline. At this level, GHRS sits in the middle of its 52-week range of $12.04 to $31.44: 44.2% below the high, set on Aug 7, 2026 and 45.6% above the low. GHRS is up 38.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 25.1%.

GH Research has posted a net loss over the last twelve months (EPS of -$0.94), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About GH Research

Company profile

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Velichka Valcheva M.D., M.Sc.
Headquarters
Dublin
Employees
73
IPO year
2021
Website
ghres.com

Financial highlights

Full financials

GH Research reported a net loss of $48.3 million, compared with a loss of $39.0 million a year earlier. Diluted earnings per share came in at -$0.79.

GH Research annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-48.26M$-38.96M$-35.59M$-22.46M$-9.20M
EPS (diluted)$-0.79$-0.75$-0.68$-0.43$-0.21

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$42.89+144.67%

  • Strong buy 3
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $38.00High $65.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.18 vs $-0.27
Surprise
+33.33%

GHRS news

All GHRS news

GH Research peers

Health Care sector
GHRS peer companies
CompanyPrice% ChgMarket capCompare
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs GHRS
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs GHRS
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs GHRS
GENBGenerate Biomedicines Inc.9.54-8.00%$1.23Bvs GHRS
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs GHRS
MNKDMannKind Corporation3.85-2.53%$1.24Bvs GHRS
OPKOPKO Health Inc.1.57-2.48%$1.17Bvs GHRS
GPCRStructure Therapeutics Inc. ADR16.13-5.78%$1.15Bvs GHRS

Indexes, lists and sector

GH Research stock FAQ

What is GH Research's stock price today?

GHRS last traded at $17.53 as of Nov 20, 4:00 PM EST, down 5.55% on the day. Prices are delayed at least 15 minutes.

Who is GH Research's CEO?

Dr. Velichka Valcheva M.D., M.Sc. is the chief executive officer of GH Research PLC, which has about 73 employees.

What is the GHRS 52-week high?

The 52-week high for GHRS is $31.44 and the 52-week low is $12.04. The stock is currently 44.2% below its high.

Compare GHRS